A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Satoh, F.; Okado, T.; Iwamoto, M.; Akita, W.; Wakabayashi, M.; Ohta, A.; Sohara, E.; Noda, Y.; Rai, T.; Uchida, S.; et al. Calcium-alkali syndrome-like symptoms manifested by daily alphacalcidol and thiazide. Intern. Med. 2010, 49, 837–840. [Google Scholar] [CrossRef]
- Kleinig, T.J.; Torpy, D.J. Milk-alkali syndrome: Broadening the spectrum of causes to allow early recognition. Intern. Med. J. 2004, 34, 366–367. [Google Scholar] [CrossRef] [PubMed]
- Hanada, S.; Iwamoto, M.; Kobayashi, N.; Ando, R.; Sasaki, S. Calcium-alkali syndrome due to vitamin D administration and magnesium oxide administration. Am. J. Kidney Dis. 2009, 53, 711–714. [Google Scholar] [CrossRef]
- Palmer, B.F.; Clegg, D.J. The use of selected urine chemistries in the diagnosis of kidney disorders. Clin. J. Am. Soc. Nephrol. 2019, 14, 306–316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khow, K.S.; Lau, S.Y.; Li, J.Y.; Yong, T.Y. Diuretic-associated electrolyte disorders in the elderly: Risk factors, impact, management and prevention. Curr. Drug Saf. 2014, 9, 2–15. [Google Scholar] [CrossRef] [PubMed]
- Lamberg, B.A.; Kuhlback, B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand. J. Clin. Lab. Investig. 1959, 11, 351–357. [Google Scholar] [CrossRef]
- Parfitt, A.M. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyrxoidism. N. Engl. J. Med. 1969, 281, 55–59. [Google Scholar] [CrossRef]
- Paillard, M.; Bichara, M. Peptide hormone effects on urinary acidification and acid-base balance: PTH, ADH, and glucagon. Am. J. Physiol. 1989, 256, F973–F985. [Google Scholar] [CrossRef]
- Girardi, A.C.; Titan, S.M.; Malnic, G.; Reboucas, N.A. Chronic effect of parathyroid hormone on NHE3 expression in rat renal proximal tubules. Kidney Int. 2000, 58, 1621–1631. [Google Scholar] [CrossRef] [Green Version]
- Sutton, R.A.; Wong, N.L.; Dirks, J.H. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int. 1979, 15, 520–533. [Google Scholar] [CrossRef] [Green Version]
- Peraino, R.A.; Suki, W.N. Urine HCO3− augments renal Ca2+ absorption independent of systemic acid-base changes. Am. J. Physiol. 1980, 238, F394–F398. [Google Scholar] [CrossRef] [PubMed]
- Punsar, S.; Somer, T. The milk-alkali syndrome. A report of three illustrative cases and a review of the literature. Acta Med. Scand. 1963, 173, 435–449. [Google Scholar] [CrossRef] [PubMed]
- Böhmig, G.A.; Schmaldienst, S.; Hörl, W.H.; Mayer, G. Iatrogenic hypercalcaemia, hypokalaemia and metabolic alkalosis in a lady with vena cava thrombosis—Beware of overzealous diuretic treatment. Nephrol. Dial. Transplant. 1999, 14, 782–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jeong, J.H.; Bae, E.H. Hypercalcemia associated with acute kidney injury and metabolic alkalosis. Electrolyte Blood Press. 2010, 8, 92–94. [Google Scholar] [CrossRef] [Green Version]
- Homler, H. Use of furosemide for milk-alkali syndrome. Mayo Clin. Proc. 2009, 84, 562. [Google Scholar] [CrossRef]
- Picolos, M.K.; Lavis, V.R.; Orlander, P.R. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin. Endocrinol. 2005, 63, 566–576. [Google Scholar] [CrossRef]
- Vassallo, P.; Green, N.; Courtney, E. Hypercalcemia secondary to excessive self-medication with antacids causing acute pancreatitis: A case report. Croat. Med. J. 2019, 60, 42–45. [Google Scholar] [CrossRef] [Green Version]
- Parvataneni, S.; Essrani, R.; Mehershahi, S.; Essrani, R.; Lohana, A.K.; Mehmood, A. Over-the-counter drug causing acute pancreatitis. J. Investig. Med. High Impact Case Rep. 2020, 8, 2324709620922724. [Google Scholar] [CrossRef]
- Vu, K.; Becker, G.; Eagerton, D. A 39-year-old woman with milk-alkali syndrome complicated by posterior reversible encephalopathy syndrome. Bone Rep. 2020, 12, 100278. [Google Scholar] [CrossRef]
- The 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS beers Criteria® for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2019, 67, 674–694. [Google Scholar] [CrossRef]
- O’Mahony, D.; O’Sullivan, D.; Byrne, S.; O’Connor, M.N.; Ryan, C.; Gallagher, P. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 2. Age Ageing 2015, 44, 213–218. [Google Scholar] [CrossRef] [Green Version]
- Hamano, J.; Tokuda, Y. Risk factors and specific prescriptions related to inappropriate prescribing among Japanese elderly home care patients. Gen. Med. 2014, 15, 117–125. [Google Scholar] [CrossRef]
- Bories, M.; Bouzillé, G.; Cuggia, M.; Le Corre, P. Drug-drug interactions in elderly patients with potentially inappropriate medications in primary care, nursing home and hospital settings: A systematic review and a preliminary study. Pharmaceutics 2021, 13, 266. [Google Scholar] [CrossRef] [PubMed]
- Fushiki, Y.; Kinoshita, K.; Tokuda, Y. Polypharmacy and adverse drug events leading to acute care hospitalization in Japanese elderly. Gen. Med. 2014, 15, 110–116. [Google Scholar] [CrossRef] [Green Version]
- Mangin, D.; Bahat, G.; Golomb, B.A.; Mallery, L.H.; Moorhouse, P.; Onder, G.; Petrovic, M.; Garfinkel, D. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position statement and 10 recommendations for action. Drugs Aging 2018, 35, 575–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bloomfield, H.E.; Greer, N.; Linsky, A.M.; Bolduc, J.; Naidl, T.; Vardeny, O.; MacDonald, R.; McKenzie, L.; Wilt, T.J. Deprescribing for community-dwelling older adults: A systematic review and meta-analysis. J. Gen. Intern. Med. 2020, 35, 3323–3332. [Google Scholar] [CrossRef] [PubMed]
Parameter | Recorded Value | Standard Value/Reference Range |
---|---|---|
White blood cell count | 9100/µL | 4500–7500/µL |
Hemoglobin | 9.3 g/dL | 11.3–15.2 g/dL |
Platelet count | 7.5 × 104/µL | 13–35 × 103/µL |
C-reactive protein | 0.24 mg/L | ≤0.60 mg/dL |
Total protein | 6.9 g/dL | 6.9–8.4 g/dL |
Albumin | 4.2 g/dL | 3.9–5.1 g/dL |
Total bilirubin | 0.7 mg/dL | 0.2–1.2 mg/dL |
Aspartate aminotransferase | 30 U/L | 11–30 U/L |
Alanine aminotransferase | 9 U/L | 4–30 U/L |
Lactase dehydrogenase | 226 U/L | 109–216 U/L |
Creatine kinase | 273 U/L | 40–150 U/L |
Blood urea nitrogen | 42.3 mg/dL | 8–20 mg/dL |
Creatinine | 1.49 mg/dL | 0.63–1.03 mg/dL |
Sodium | 145 mEq/L | 136–148 mEq/L |
Potassium | 1.7 mEq/L | 3.6–5.0 mEq/L |
Chloride | 91 mEq/L | 98–108 mEq/L |
Calcium | 15.2 mg/dL | 8.8–10.1 mg/dL |
Phosphorus | 1.5 mg/dL | 2.7–4.6 mg/dL |
Magnesium | 1.5 mg/dL | 1.8–2.6 mg/dL |
Glucose | 144 mg/dL | 70–109 mg/dL |
Hemoglobin A1c | 5.1% | 5.6–5.9% |
Tests related to hypercalcemia (day 2) | ||
Angiotensin-converting enzyme | 6.8 U/L | 7.0–25.0 U/L |
1,25-dihydroxyvitamin D3 | 27 pg/mL | 20.0–60.0 pg/mL |
Intact parathyroid hormone | 14 pg/mL | 15.0–65.0 pg/mL |
Parathyroid hormone-related protein-C | <1.1 pmol/L | <1.1 pmol/L |
Venous blood gas analysis | ||
pH | 7.546 | |
pCO2 | 50.3 mmHg | |
HCO3− | 43.6 mEq/L | |
Base excess | 19.0 mEq/L | |
Urinalysis | ||
pH | 7.0 | |
Specific gravity | 1.011 | |
Protein | +/− | |
Occult blood | 2+ | |
Sodium | 37 mEq/L | |
Potassium | 18.5 mEq/L | |
Chloride | 30 mEq/L | |
Calcium | 15.7 mg/dL | |
Phosphorus | 22.0 mg/dL | |
Magnesium | 3.1 mg/dL |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mizutani, N.; Goda, K.; Kenzaka, T. A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy. Medicina 2023, 59, 1345. https://doi.org/10.3390/medicina59071345
Mizutani N, Goda K, Kenzaka T. A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy. Medicina. 2023; 59(7):1345. https://doi.org/10.3390/medicina59071345
Chicago/Turabian StyleMizutani, Naoya, Ken Goda, and Tsuneaki Kenzaka. 2023. "A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy" Medicina 59, no. 7: 1345. https://doi.org/10.3390/medicina59071345